Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice

Pharmacogenomics Journal

Volumn 8, Issue 3, 2008, Pages 196-208

  Steiner, M A ^a,b   Wanisch, K ^a   Monory, K ^b   Marsicano, G ^b,c   Borroni, E ^d   Bachli H ^e   Holsboer, F ^a   Lutz, B ^b   Wotjak, C T ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID 1 RECEPTOR; DESIPRAMINE; ENDOCANNABINOID; MESSENGER RNA; PAROXETINE; RIMONABANT; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; COPING BEHAVIOR; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG SPECIFICITY; ENZYME ACTIVITY; FEMALE; FORCED SWIMMING TEST; GENE EXPRESSION; GENE INACTIVATION; GENOTYPE; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STRESS;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; BIOGENIC MONOAMINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; DESIPRAMINE; FEMALE; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; SWIMMING; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

ANIMALIA; MUS;

EID: 44049107528     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500466     Document Type: Article

References (51)

1. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-884.
2. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al. CB1 cannabinoid receptors and on-demand defense against excltotoxicity. Science 2003; 302: 84-88.
3. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006; 51: 455-466.
4. Degroot A, Kofalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N et al CB1 receptor antagonism increases hippocampa! acetylcholine release: site and mechanism of action. Mol Pharmacol 2006; 70: 1236-1245.
5. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP et al The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003; 138 544-553.
6. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M et al. Antidepressant-like activity and modulation of brain mono-aminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-18625.
7. Wotjak CT. Role of endogenous cannabinoids in cognition and emotionality. Min Rev Med Chem 2005; 5: 659-670.
8. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-534.
9. Kamprath K, Marsicano G, Tang J, Monory K, Bisogno T, Di Marzo et al Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 2006; 26: 6677-6686.
10. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
11. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence.for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006; 318: 304-311.
12. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81: 331-342.
13. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 2005; 16: 333-352.
14. Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004; 15: 299-304.
15. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002; 16: 1395-1398.
16. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002; 159: 379-387.
17. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005; 57: 261-267.
18. Rodgers RJ, Evans PM, Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 2005; 16: 405-413.
19. Haller J, Varga B, Ledent C, Bama I, Freund TF. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004; 19: 1906-1912.
20. Merikangas KR, Zhang HP, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study - The Zurich cohort study. Arch Gen Psychiatry 2003; 60: 993-1000.
21. Witkin JM, Tzavara ET, Nomikos GG. A role for-cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005; 16: 315-331.
22. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 2004; 176: 223-232.
23. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R et al Endogenous cannabinoid system as a modulator of food intake. Int J Obes 2003; 27: 289-301.
24. Bilkei-Gorzo A, Racz I, Valverde O, Otto M, Michel K, Sarstre M et al Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc Natl Acad Sci USA 2005; 102: 15670-15675.
25. Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grubler Y et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2006; 148: 1574-1581.
26. Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B et al The endocannabinoid system drives neural progenitor proliferation. FASEB J 2005; 19: 1704-1706.
27. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB et al. Upregulation of CB1 receptors and agonist-stimulated [S-35]GTP gamma S binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004; 9: 184-190.
28. Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide. Biol Psychiatry 2005; 57: 480-486.
29. Pi-Sunyer FX, Aronne W, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006, 295: 761-775.
30. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
31. Van Gaal LF, Rissanen AM, Scheen AI, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
32. Cryan IF, Holmes A. The ascent of mouse: Advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005; 4: 775-790.
33. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2004; 15: 593-599.
34. Jardinaud F, Crete D, Canestrelli C, Ledent C, Roques BP, Noble F. CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited. Brain Res 2005; 1063: 77-83.
35. Kessler RC, Mcgonagle KA Zhao SY, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of IDSM-III-R psychiatric-disordern in the United-States - results from the National-Comorbidity-Survey. Arch Gen Psychiatry 1994; 51: 8-19.
36. Moutsimilli L, Farley S, Dumas S, El Mestikawy S, Giros B, Tzavara ET. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 2005; 49: 890-900.
37. Shirayama Y, Chen ACH, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-3261.
38. Wei Q, Lu XY, Liu L, Schafer G, Shieh KR, Burke S et al. Glucocorticoid receptor overexpression in forebrain: A mouse model of increased emotional lability. Proc Natl Acad Sci USA 2004; 101 11851-11856.
39. Uriguen I, Perez-Rial S, Ledent C, Palomo T, Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 2004; 46: 966-973.
40. Gobshtis N, Ben Shabat S, Fride E. Antidepressant-induced undesirable weight gain: Prevention with rimonabant without interference with behavioral effectiveness. Eur J Pharmocol 2007; 554: 155-163.
41. Lucki I, O'Leary OF. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 2004; 65: 11-24.
42. Shih JC. Cloning, after cloning, knock-out mice, and physiological functions of MAO A and B. Neurotoxicology 2004; 25: 21-30.
43. Khaspekov LG, Verca MSB, Frumkina LE, Hermann H, Marsicano G, Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 2004; 19: 1691-1698.
44. Cryan JF, Holmes A. The ascent of mouse: Advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005; 4: 775-790.
45. McArthur R, Borsini F. Animal models of depression in drug discovery: A historical perspective. Pharmacol Biochem Behav 2006, 84: 436-452.
46. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001; 155: 315-322.
47. West AP. Neurobehavioral studies of forced swimming - the role of learning and memory in the forced swim test. Prog Neuropsychopharmacol Biol Psych 1990; 14: 863-877.
48. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology 2005; 177 245-255.
49. Urani A, Chourbaji S, Gass P. Mutant mouse models of depression: candidate genes and current mouse lines. Neurosci Biobehav Rev 2005; 29: 805-828.
50. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9: 984-997.
51. Zhou MJ, PanchukVoloshina N. A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal Biochem 1997; 253: 169-174.